登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，3月20日，SARS-CoV-2 specific antibody responses in COVID-19 patients》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-22

  • SARS-CoV-2 specific antibody responses in COVID-19 patients

    NISREEN M.A. OKBA, Marcel A Muller, Wentao Li, Chunyan Wang, Corine H. GeurtsvanKessel, Victor M. Corman, Mart M. Lamers, Reina S. Sikkema, Erwin de Bruin, Felicity D. Chandler, Yazdan Yazdanpanah, Quentin Le Hingrat, Diane Descamps, Nadhira Houhou-Fidouh, Chantal B. E. M. Reusken, Berend-Jan Bosch, Christian Drosten, Marion P.G. Koopmans, Bart L. Haagmans

    doi: https://doi.org/10.1101/2020.03.18.20038059

    Abstract

    A new coronavirus, SARS-CoV-2, has recently emerged to cause a human pandemic. Whereas molecular diagnostic tests were rapidly developed, serologic assays are still lacking, yet urgently needed. Validated serologic assays are important for contact tracing, identifying the viral reservoir and epidemiological studies. Here, we developed serological assays for the detection of SARS-CoV-2 neutralizing, spike- and nucleocapsid-specific antibodies. Using serum samples from patients with PCR-confirmed infections of SARS-CoV-2, other coronaviruses, or other respiratory pathogenic infections, we validated and tested various antigens in different in-house and commercial ELISAs.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.18.20038059v1
139浏览量
原文链接
相关报告

  • 《MedRxiv，4月20日，（第2版更新）Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-29
    • Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Fan Wu, Aojie Wang, Mei Liu, Qimin Wang, Jun Chen, Shuai Xia, Yun Ling, Yuling Zhang, Jingna Xun, Lu Lu, Shibo Jiang, Hongzhou Lu, Yumei Wen, Jinghe Huang doi: https://doi.org/10.1101/2020.03.30.20047365 Abstract Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease. However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients. Methods Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudotyped-lentiviral-vector-based neutralization assay. Spike-binding antibody in plasma were determined by ELISA using RBD, S1, and S2 proteins of SARS-CoV-2. The levels and the time course of SARS-CoV-2-specific NAbs and the spike-binding antibodies were monitored at the same time. Findings SARS-CoV-2 NAbs were unable to cross-reactive with SARS-CoV virus. SARS-CoV-2-specific NAbs were detected in patients from day 10-15 after the onset of the disease and remained thereafter. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    87浏览量
    原文链接

  • 《MedRxiv，3月20日，Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-22
    • Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice Quan-xin Long, Hai-jun Deng, Juan Chen, Jieli Hu, Bei-zhong Liu, Pu Liao, Yong Lin, Li-hua Yu, Zhan Mo, Yin-yin Xu, Fang Gong, Gui-cheng Wu, Xian-xiang Zhang, Yao-kai Chen, Zhi-jie Li, Kun Wang, Xiao-li Zhang, Wen-guang Tian, Chang-chun Niu, Qing-jun Yang, Jiang-lin Xiang, Hong-xin Du, Hua-wen Liu, Chunhui Lang, Xiao-he Luo, Shao-bo Wu, Xiao-ping Cui, Zheng Zhou, Jing Wang, Cheng-jun Xue, Xiao-feng Li, Li Wang, Xiao-jun Tang, Yong Zhang, Jing-fu Qiu, Xia-mao Liu, Jin-jing Li, De-chun Zhang, Fan Zhang, Xue-fei Cai, Deqiang Wang, Yuan Hu, Ji-hua Ren, Ni Tang, Ping Liu, Qin Li, Ai-long Huang doi: https://doi.org/10.1101/2020.03.18.20038018 Abstract Background We aim to investigate the profile of acute antibody response in COVID-19 patients, and provide proposals for the usage of antibody test in clinical practice. Methods A multi-center cross-section study (285 patients) and a single-center follow-up study (63 patients) were performed to investigate the feature of acute antibody response to SARS-CoV-2. A cohort of 52 COVID-19 suspects and 64 close contacts were enrolled to evaluate the potentiality of the antibody test. Results The positive rate for IgG reached 100% around 20 days after symptoms onset. The median day of serocon-version for both lgG and IgM was 13 days after symptoms onset. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    129浏览量
    原文链接